AstraZeneca's Farxiga Approved For Treating Pediatric Type-2 Diabetes in U.S.
By Ben Glickman
AstraZeneca's diabetes drug Farxiga on Wednesday was approved by U.S. regulators for the treatment of type-2 diabetes in children 10 and older.
Farxiga, which goes by generic name dapagliflozin, was already approved by the U.S. Food and Drug Administration in adults with type-2 diabetes, when used as an adjunct to diet and exercise to improve glycemic control.
The pharmaceutical company said the approval was based on results in a pediatric Phase 3 trial. AstraZeneca said the trial showed a statistically significant improvement in glycemia for children and adolescents with the disease.
Farxiga is already approved for treating pediatric type-2 diabetes patients in 56 countries, including the European Union. The medicine is sold under the brand name Forxiga in the EU.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
June 12, 2024 18:16 ET (22:16 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Best- and Worst-Performing Stocks of Q2 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations